AbbVie Shares Slide 1.6% Despite Analysts’ 22% Q1 EPS Growth Forecast
AbbVie shares fell 1.63%, lagging the S&P 500’s 0.57% drop after an 8.79% one-month rally versus the Medical sector’s 0.06% gain. Analysts forecast Q1 EPS of $3.01 (+22.4% yoy) on $14.77 billion revenue (+10.7%), with a forward P/E of 16.25 and PEG of 0.83.
1. Stock Underperformance
In the latest session, AbbVie’s shares declined 1.63%, underperforming the S&P 500’s 0.57% drop and trailing the Dow’s 1.61% and Nasdaq’s 0.26% losses. The relative weakness highlights pressure on the stock amid broader market declines.
2. One-Month Rally vs Sector
Over the past month, AbbVie’s stock gained 8.79%, outpacing the Medical sector’s 0.06% rise and the S&P 500’s 0.15% loss. This rally reflects renewed investor interest following earlier volatility.
3. Upcoming Earnings Projections
Analysts project first-quarter EPS of $3.01, a 22.36% increase year-over-year, on revenue of $14.77 billion, up 10.68%. These estimates build anticipation ahead of AbbVie’s upcoming earnings release.
4. Valuation and Analyst Outlook
AbbVie trades at a forward P/E of 16.25, matching its industry average, and holds a PEG ratio of 0.83 versus the industry’s 2.31. Consensus EPS estimates have risen 2.06% over the past month, and the stock carries a neutral analyst rating.